GlassScriptPhysician profile
Marla Mullen
NPI 1457496911
$1,597.00
in general payments reported to CMS, 2019-2025
13 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2022: $74.91 · 2023: $512 · 2024: $320 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.33 | 2021-2023 | |
| Dexcom, INC. | $212.04 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Abbvie INC. | $151.23 | 2022-2024 | |
| Biogen, INC. | $148.92 | 2023-2024 | |
| Daiichi Sankyo INC. | $107.91 | 2025 | Injectafer |
| Amgen INC. | $103.03 | 2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $97.69 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $85.40 | 2023 | Quviviq |
| Novo Nordisk INC | $85.25 | 2021 | |
| Sage Therapeutics, LLC | $79.73 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $76.32 | 2024 | Uzedy |
| Sanofi Pasteur INC. | $75.68 | 2023 | |
| Impel Pharmaceuticals INC. | $71.47 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.